

DOWRGONNA (PHARMA) CONSULTING LIMITED

**Company Registration Number:
11250014 (England and Wales)**

**Unaudited micro entity accounts for the year ended 31 March 2022
(Dormant)**

Period of accounts

Start date: 01 April 2021

End date: 31 March 2022

DOWRGONNA (PHARMA) CONSULTING LIMITED

Contents of the Financial Statements

for the Period Ended 31 March 2022

Company Information - 3

Report of the Directors - 4

Profit and Loss Account - 5

Balance sheet - 6

Footnotes to the Balance Sheet - 8

DOWRGONNA (PHARMA) CONSULTING LIMITED

Company Information

for the Period Ended 31 March 2022

Director: Andrew James

Registered office: 3
Higher Tamar Terrace
Gunnislake
GBR
PL18 9LP

Company Registration Number: 11250014 (England and Wales)

DOWRGONNA (PHARMA) CONSULTING LIMITED

Directors' Report Period Ended 31 March 2022

The directors present their report with the financial statements of the company for the period ended 31 March 2022

Directors

The directors shown below have held office during the whole of the period from 01 April 2021 to 31 March 2022

Andrew James

The company was dormant and did not trade in the period.

This report was approved by the board of directors on 9 July 2022

And Signed On Behalf Of The Board By:

Name: Andrew James

Status: Director

DOWRGONNA (PHARMA) CONSULTING LIMITED

Profit and Loss Account

for the Period Ended 31 March 2022

The company was dormant and did not trade in the period. The company received no income and incurred no expenditure in the period and therefore did not make either a profit or loss.

DOWRGONNA (PHARMA) CONSULTING LIMITED

Balance sheet

As at 31 March 2022

	<i>2022</i> £	<i>2021</i> £
Called up share capital not paid:	0	0
Fixed Assets:	0	0
Current assets:	0	0
Prepayments and accrued income:	0	0
Creditors: amounts falling due within one year:	(0)	(0)
Net current assets (liabilities):	<u>0</u>	<u>0</u>
Total assets less current liabilities:	0	0
Creditors: amounts falling due after more than one year:	(0)	(0)
Provision for liabilities:	(0)	(0)
Accruals and deferred income:	(0)	(0)
Total net assets (liabilities):	<u>0</u>	<u>0</u>
Capital and reserves:	<u>0</u>	<u>0</u>

DOWRGONNA (PHARMA) CONSULTING LIMITED

Balance sheet continued

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared and delivered in accordance with the provisions of the small companies regime applicable to micro-entities.

For the year ending 31 March 2022 the company was entitled to exemption under section 480 of the Companies Act 2006 relating to dormant companies.

This report was approved by the board of directors on 9 July 2022

And Signed On Behalf Of The Board By:

Name: Andrew James

Status: Director

The notes form part of these financial statements

DOWRGONNA (PHARMA) CONSULTING LIMITED

Footnotes to the Financial Statements

for the Period Ended 31 March 2022

1. Employee Information

Average number of employees: 1

DOWRGONNA (PHARMA) CONSULTING LIMITED

Footnotes to the Financial Statements

for the Period Ended 31 March 2022

2. Off balance sheet disclosure

No

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.